Regulatory News:
Transgene SA (Euronext Paris: FR0005175080) (Paris:TNG) today announces the following financial reporting dates for 2013:
March 22, 2013: | 2012 Annual Results and Strategic Update | |
April 22, 2013 | Q1 Financial Report | |
June 19, 2013: | Annual Shareholders' Meeting | |
September 12, 2013: | Half-Year Financial Report | |
October 21, 2013: | Q3 Financial Report |
About Transgene:
Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and JX594/TG6006 having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded strategic agreements for the development of two of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers and an in-licensing agreement with US-based Jennerex, Inc. to develop and market JX594/TG6006, an oncolytic virus. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.
Société anonyme au capital de 72.523.405 ? - R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166 - 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 (0)3 88 27 91 00
Transgene
Stéphane Boissel, Executive Vice President & CFO
+33
(0)3 88 27 91 02
or
Elisabetta Castelli, Director IR
+33
(0)3 88 27 91 21
or
MC Services
Raimund Gabriel,
+49 89 210 228 30
or
Shaun Brown, +44 207 148 5998